Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JSP Pharmaceutical Manufacturing (Thailand) PCL has a Cash Ratio of 0.17. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
JSP Pharmaceutical Manufacturing (Thailand) PCL Cash Ratio Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL Cash Ratio Chart
JSP Pharmaceutical Manufacturing (Thailand) PCL Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL Cash Ratio vs Consumer Packaged Goods Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) has a Cash Ratio of 0.17 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. This is 15% below median its historical median of 0.20. Over the past decade, JSP Pharmaceutical Manufacturing (Thailand) PCL's Cash Ratio has ranged from 0.11 to 6.04. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1302 out of 1919 companies in the Consumer Packaged Goods industry, placing it in the top 67.8%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Cash Ratio too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Cash Ratio of 0.17 is 15% below median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 6.04. The Consumer Packaged Goods industry median Cash Ratio is 0.39. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 0.17 is 56.4% below this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1302 out of 1919 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Cash Ratio compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1302 out of 1919 companies for Cash Ratio. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the lower half of its industry. The industry median Cash Ratio is 0.39. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 0.17 is 56.4% below this benchmark. Historically, JSP Pharmaceutical Manufacturing (Thailand) PCL's own Cash Ratio has ranged from 0.11 to 6.04 over the past decade. While the company's 10-year median is 0.20 vs. the industry median of 0.39, JSP Pharmaceutical Manufacturing (Thailand) PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Consumer Packaged Goods company?
The median Cash Ratio among Consumer Packaged Goods companies is 0.39, based on 1,919 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Cash Ratio of 0.17 is 56.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median Cash Ratio is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Cash Ratio is 0.17, which is 15% below median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.18, compared to a current price of ฿1.75 — trading 19.9% below its estimated fair value. The current Cash Ratio is 0.17, which is 15% below median its 10-year median of 0.20 and 56.4% below the Consumer Packaged Goods industry median of 0.39. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R), the current Cash Ratio is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.75 is trading 19.9% below its estimated GF Value™ of ฿2.18.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Modestly Undervalued.
Key valuation signals for BKK:JSP-R:
Cash Ratio: 0.17 (15% below median its 10-year median of 0.20)
GF Value™: ฿2.18 vs. price of ฿1.75 (19.9% below fair value)
Industry Position: 56.4% below the Consumer Packaged Goods median (#1302 of 1919)
No single metric tells the full story. See the BKK:JSP-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score
Get the complete analysis for BKK:JSP-R
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP-R has been successfully added to your 
